As genomics-based discovery companies come closer to clinical trials and readying drugs for market, there’s increasing concern about FDA regulations. That’s why at a recent seminar hosted by Washington law firm King & Spalding people in the field stressed the importance of working with the FDA.

The agency is “no paper tiger,” says Mark Brown of King & Spalding’s FDA Practice Group. “It has enormous enforcement power, and can destroy companies and careers.”